[Digestive manifestations in systemic sclerosis]
- PMID: 12218892
[Digestive manifestations in systemic sclerosis]
Abstract
Gastrointestinal involvement occurs in most patients with systemic sclerosis. Pathology is characterized by vasculopathy, resulting in tissue ischemia, progressive dysfunction and fibrosis. In its diffuse and visceral pattern, digestive manifestations may involve most of the intestinal tract and are the most frequent before renal, cardiac and pulmonary involvement. Whatever the visceral extension, about 80% of patients have digestive manifestations including gastroesophageal reflux, abnormalities of intestinal motility leading to chronic intestinal pseudo-obstruction and small bowel bacterial overgrowth and malnutrition. Long-term treatment of reflux with high-dose proton pump inhibitors appears safe and effective for symptom relief and may prevent recurrence of esophagitis and stricture. Prokinetic agents effective in pseudoobstruction include metoclopramide, domperidone, octreotide, and erythromycin.
Similar articles
-
Gastrointestinal manifestations of progressive systemic sclerosis.Am J Gastroenterol. 1997 May;92(5):763-71. Am J Gastroenterol. 1997. PMID: 9149182 Review.
-
Esophageal involvement in scleroderma: gastroesophageal reflux, the common problem.Semin Arthritis Rheum. 2006 Dec;36(3):173-81. doi: 10.1016/j.semarthrit.2006.08.002. Epub 2006 Oct 11. Semin Arthritis Rheum. 2006. PMID: 17045629 Review.
-
[Clinical aspects, pathophysiology, diagnosis and therapy of gastrointestinal manifestations of progressive systemic scleroderma].Z Gastroenterol. 1996 Aug;34(8):497-508. Z Gastroenterol. 1996. PMID: 8967123 Review. German.
-
[Systemic sclerosis].Med Monatsschr Pharm. 2008 May;31(5):162-70; quiz 171-2. Med Monatsschr Pharm. 2008. PMID: 18552072 Review. German.
-
[Small bowel pseudo-obstruction revealing an early scleroderma. Long-term efficacy of octreotide and erythromycin].Gastroenterol Clin Biol. 2000 Mar;24(3):361-3. Gastroenterol Clin Biol. 2000. PMID: 10804347 French.
Cited by
-
Evaluation and management of esophageal manifestations in systemic sclerosis.Ann Gastroenterol. 2018 Mar-Apr;31(2):165-170. doi: 10.20524/aog.2018.0228. Epub 2018 Jan 18. Ann Gastroenterol. 2018. PMID: 29507463 Free PMC article. Review.
-
Systemic sclerosis and the gastrointestinal tract.Prz Gastroenterol. 2017;12(3):163-168. doi: 10.5114/pg.2017.70467. Epub 2017 Sep 30. Prz Gastroenterol. 2017. PMID: 29123575 Free PMC article. Review.
-
Creation and Validation of a Portuguese Version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.Int J Environ Res Public Health. 2023 Jan 14;20(2):1553. doi: 10.3390/ijerph20021553. Int J Environ Res Public Health. 2023. PMID: 36674306 Free PMC article.
-
Validation of the Portuguese Version of the Scleroderma Health Assessment Questionnaire.Int J Environ Res Public Health. 2023 Nov 14;20(22):7062. doi: 10.3390/ijerph20227062. Int J Environ Res Public Health. 2023. PMID: 37998293 Free PMC article.
-
Anorectal motility and sensation abnormalities and its correlation with anorectal symptoms in patients with systemic sclerosis: a preliminary study.ISRN Gastroenterol. 2011;2011:402583. doi: 10.5402/2011/402583. Epub 2011 Jun 6. ISRN Gastroenterol. 2011. PMID: 21991506 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical